arrow
C

Christine Galant

universite catholique louvain
H指数:34
被引数:3,911

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An Immunohistochemistry-based Decision Flowchart to De-escalate Axillary Surgery for Biopsy-Diagnosed Pure Ductal Carcinoma In Situ (DCIS) of the Breast

基于免疫组化技术的决策流程图,用于减少对活检确诊为乳腺纯导管原位癌(DCIS)患者的腋窝手术

2026-08-010
PRE
Reproducibility of Equivocal HER2 In Situ Hybridization Groups 3 and 4, and Comparison With HER2 mRNA Expression

HER2原位杂交结果为可疑的3组和4组的可重复性及与HER2 mRNA表达的对比

2025-12-010
PRE
Evaluation of short-course durvalumab combined with dose-dense EC in the neoadjuvant setting for locally advanced luminal B/HER2(-) or triple-negative breast cancer

评估短疗程度伐利尤单抗联合高密度EC方案在局部晚期luminal B/HER2(-)或三阴性乳腺癌新辅助治疗中的效果

2025-11-280
OAAI
Jacaric Acid Empowers RSL3-Induced Ferroptotic Cell Death in Two- and Three-Dimensional Breast Cancer Cell Models

Jacaric Acid 增强 RSL3 诱导的铁死亡在二维和三维乳腺癌细胞模型中的细胞死亡

2025-04-040
OA
Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial-mesenchymal transition and tumor-infiltrating lymphocytes

早期乳腺癌对新辅助化疗的反应与上皮间质转化和肿瘤浸润淋巴细胞有关

2025-02-060
OAAI
Reproducibility of equivocal HER2 in situ hybridisation (ISH) results in invasive breast cancer, and correlation with HER2 mRNA expression as determined by Mammatyper®

浸润性乳腺癌中HER2原位杂交(ISH)结果的可重复性,以及与Mammatyper®测定的HER2 mRNA表达的相关性

BREAST
IF7.9
2025-02-010
OAAI
B-IMMUNE final analysis: a phase Ib/II study of durvalumab combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers
2023-03-010
PRE
Timing evolution of lobular breast cancer through phylogenetic analysis
2022-08-017
OAAI
B-immune interim analysis: A phase Ib/II study of durvalumab combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers
2022-02-150
PRE
Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study
2021-12-0122
OAAI